· Published by Health Canada · Official notice
This is duplicated text of a letter from LEO Pharma Inc.
Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
October 19, 2010
Subject: Updated safety information on the Use of INNOHEP® (tinzaparin sodium) in Elderly Patients with Renal Impairment
LEO Pharma, in consultation with Health Canada, has informed Canadian healthcare professionals of important updated safety information concerning INNOHEP (tinzaparin sodium) from a clinical study that was stopped prematurely (the IRIS study) due to an increase in the number of deaths observed. The study involved the use of INNOHEP in elderly patients with poor kidney function being treated for new blood clots.
INNOHEP is approved for the prevention and treatment of blood clots and works to prevent blood clots from forming or getting bigger.
The IRIS study (INNOHEP in Renal Insufficiency Study) was an international study comparing doses of INNOHEP and unfractionated heparin for the treatment of blood clots in elderly patients (over 70 years old) with poor kidney function. During the study, there were more deaths seen in the patients treated with INNOHEP (11.5%) than those treated with heparin (6.3%). Based on these observations the study was stopped. There was no clear explanation for this difference; however these deaths were not due to blood clots or bleeding.
The Canadian Product Monograph (the prescribing information) for INNOHEP has been revised to include this updated information and can be accessed at www.leo-pharma.com/canada or in Health Canada's Drug Product Database.
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any serious or unexpected adverse reactions in patients receiving INNOHEP should be reported to LEO Pharma Inc. or Health Canada at the following addresses:
LEO Pharma Inc.
123 Commerce Valley Drive East, Suite 400
Thornhill, Ontario, L3T 7W8
or call toll free Medical Info at: 1-800-263-4218
or fax at: 905-886-6639
or e-mail at: medical-info.ca@leo-pharma.com
You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following three ways:
The Reporting Forms, postage paid labels, and Guidelines can be found on the MedEffect™ Canada Web site in the Adverse Reaction Reporting section.
For other health product inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate
E-mail: mhpd_dpsc@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738
Should you have any questions or require additional information regarding the use of INNOHEP, please contact the Medical Information Department of LEO Pharma Inc. at 1-800-263-4218.
Sincerely,
original signed by
Kenneth Kobayashi, MD, FRCPC
Vice President, Research & Development
LEO Pharma Inc.
® Registered trademark of LEO Pharma A/S used under license by LEO Pharma Inc. Thornhill, ON